Breaking news

Ozempic Approved By FDA For Chronic Kidney Disease Treatment

by THEFUTURE.TEAM

January 29, 2025

The U.S. Food and Drug Administration (FDA) has approved Ozempic for the treatment of patients with chronic kidney disease, marking a new milestone for Novo Nordisk’s highly popular drug, previously authorized for type 2 diabetes and weight loss.

Key Facts

The FDA approval allows Ozempic to be used to reduce the risk of kidney disease progression, kidney failure, and death from cardiovascular events in patients with type 2 diabetes and chronic kidney disease.
The approval is based on a late-stage trial involving more than 3,500 participants, which showed that Ozempic lowered the risk of kidney disease progression and death from kidney or cardiovascular complications by 24% compared to a placebo.
Patients using Ozempic also experienced slower rates of kidney decline, according to Novo Nordisk.

In December 2024, the European Union’s health regulators also gave the go-ahead for Novo Nordisk to expand Ozempic’s label, indicating that the drug could reduce the risk of chronic kidney disease-related events in adults with type 2 diabetes.

Follow THE FUTURE on LinkedIn, Facebook, Instagram, X and Telegram

Surprising Fact

The Centers for Disease Control and Prevention (CDC) estimates that one in every three adults with diabetes suffers from chronic kidney disease. Diabetes, both type 1 and type 2, can impair kidney function due to its effects on the kidneys’ ability to filter waste, compounded by the high blood pressure that often accompanies the condition.

What Has Ozempic Been Approved For?

Ozempic has already been approved by the FDA for type 2 diabetes management, and it’s also widely used off-label for weight loss. Additionally, the FDA authorized Novo Nordisk’s Wegovy—which contains the same active ingredient, semaglutide—for weight loss and lowering the risk of cardiovascular events, such as heart attacks and strokes.

Key Background

Ozempic and Wegovy are part of the GLP-1 agonist class of medications, which mimic the function of a gut hormone responsible for regulating blood sugar and appetite. Research into the broader benefits of these drugs has been growing. For example, Eli Lilly’s Zepbound, a competitor, was recently approved for treating obesity and sleep apnea, after it was shown to significantly reduce apnea events in a clinical trial.

Other studies suggest GLP-1 drugs might also have potential applications in treating alcohol use disorder and improving mood, cognitive function, and symptoms in patients with conditions like Parkinson’s, Alzheimer’s, dementia, bipolar disorder, and anxiety.

The Future Forbes Realty Global Properties

Google Escalates Capital Outlay Amid Surge in Cloud Demand

by THEFUTURE.TEAM

July 25, 2025

Robust Investment Strategy To Power AI Innovation

Alphabet Inc. has significantly revised its capital spending forecast for 2025, allocating an additional $10 billion to accommodate the burgeoning demand for its Cloud services. This strategic move reflects the company’s proactive approach to expanding its infrastructure, particularly in light of the accelerated adoption of AI-powered solutions.

Expanding Infrastructure To Meet Unprecedented Demand

In its second quarter earnings report, Alphabet highlighted a sharp increase in cloud revenues—up 32% to $13.6 billion. This surge has precipitated a $106 billion service backlog, as noted by Finance Chief Anat Ashkenazi during the post-earnings call. The majority of the additional capital expenditure is earmarked for enhancing technical infrastructure, with investments focused on servers and data center networking equipment. The company’s renewed forecast now stands at approximately $85 billion in capital expenditures for 2025, up from the previously projected $75 billion.

Follow THE FUTURE on LinkedIn, Facebook, Instagram, X and Telegram

Strategic Expansion Amid A Tight Supply Environment

Ashkenazi pointed out the challenges posed by a tight supply environment, emphasizing that the accelerated pace of server deployments and data center construction is essential to keeping pace with client demand. As Google continues to enhance capacity quarter-by-quarter, further increased capital spending is anticipated in 2026 to capitalize on emerging growth opportunities across the organization.

Implications For Future Profitability

While these significant investments will position Google at the forefront of AI and Cloud technology, they also imply a measurable increase in expenses, potentially affecting short-term profitability. Nevertheless, this forward-looking expansion underscores Alphabet’s commitment to sustaining its competitive edge in a rapidly evolving technological landscape.